jain.com
The Analysis · Companies · People · Methodology

Term loan maturity extension contingency

Company: TeraWulf

This claim was marked delayed on September 14, 2026. Recorded automatically from the cited source when it was published, then queued for evidence review.

How this was decided: Automated extraction from the cited source. The claim is preserved below exactly as it was originally published, so the record shows what was asserted as well as what became of it.

Subject kind
financing
Statement date
2023-03-30
Promised by
2024-04-01
Promised amount
40.0 USD million
Current status
delayed

The claim, verbatim

Excess cash flow sweep extends term loan maturity to December 1, 2024 if Company repays at least 40 million dollars of principal by April 1, 2024

Source (primary)

TeraWulf 10-K filed 2023-03-31 (SEC EDGAR, sec_filing)
View cached copy (2026-09-13)Live source ↗

Quote: “the excess cash flow sweep in place of scheduled principal payments, which will automatically extend to the maturity of the term loan on December 1, 2024 in the event the Company repays at least $40 million of the term loan by April 1, 2024”

How we checked this

This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.

Additional evidence

confirms TeraWulf 10-K filed 2023-03-31

Quote: “the excess cash flow sweep in place of scheduled principal payments, which will automatically extend to the maturity of the term loan on December 1, 2024 in the event the Company repays at least $40 million of the term loan by April 1, 2024”

View cached copy (2026-09-13)Live source ↗

Record of changes

September 13, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
September 14, 2026 — delayed
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.